The trial enrolled thirty patients with relapsed or refractory small cell lung cancer who had already progressed after platinum-based chemotherapy, a population where effective options are scarce and median survival is typically measured in months. The treatment sequence was deliberately simple. Each patient received 24 Gy of hypofractionated radiotherapy delivered in four fractions every other day, a schedule designed to deposit substantial radiation dose in a compressed timeframe. Immediately afterward, patients began atezolizumab at 1200 mg every three weeks. The rationale rested on a growing body of preclinical and clinical evidence suggesting that radiation can do more than kill tumor cells directly. Hypofractionated doses can trigger immunogenic cell death, releasing tumor antigens and danger signals that recruit and activate immune cells, potentially converting an irradiated tumor into something resembling an in situ vaccine that checkpoint blockade can then amplify.

The clinical outcomes told a sobering story about the difficulty of treating this disease in an unselected population. The objective response rate was 80.0 percent for the radiotherapy component itself, confirming that the tumors were radiosensitive, as small cell lung cancer characteristically is. But when atezolizumab took over as the systemic agent, the response rate fell to just 16.7 percent. Median progression-free survival was 2.5 months, with only 6.9 percent of patients remaining progression-free at six months. Median overall survival reached 10.4 months, and 41.8 percent of patients were alive at one year, figures that are respectable for relapsed disease but fall short of a breakthrough. The gap between local radiosensitivity and systemic immunotherapy benefit is precisely the puzzle the trial’s exploratory immune profiling was designed to address.

That profiling began with serial blood draws. Peripheral blood mononuclear cells were collected before radiotherapy and again after its completion, then analyzed using multiparametric flow cytometry, a technique that tags cells with fluorescent antibodies and sorts them by the proteins they display on their surfaces. The investigators focused on two cell types with very different immunological roles. The first was the natural killer T cell, identified as cells carrying both CD3, a pan-T-cell marker, and CD56, a marker shared with natural killer cells. NKT cells sit at the interface of innate and adaptive immunity, capable of rapid cytokine release and of bridging radiation-induced inflammation to broader antitumor responses. The second was the classical monocyte, defined as CD14-high and CD16-negative, with particular attention to the fraction of these cells expressing programmed death-ligand 1, the same molecule that atezolizumab blocks.

The NKT cell findings were the trial’s first revelation. Patients whose disease remained controlled for three months or longer on progression-free survival started with significantly lower circulating NKT cell frequencies at baseline than patients who progressed sooner, a difference that reached statistical significance at p equals 0.02. More striking still was what happened after radiation. In the longer-survival group, NKT cell numbers expanded after radiotherapy, with a median fold-change of 1.3, while in the shorter-survival group they contracted, with a fold-change of 0.9. The difference between these trajectories was statistically significant at p equals 0.011. In other words, the direction of change, not simply the starting point, carried prognostic information. A radiation-induced surge in these innate-like lymphocytes in the bloodstream appeared to mark patients whose immune systems could be mobilized into a durable antitumor posture.

The monocyte data told a complementary story. Classical monocytes are the most abundant monocyte subset in human blood, and when they express PD-L1, they are often interpreted as soldiers of an immunosuppressive program, cells that dampen T-cell activity and can be recruited by tumors as shields against immune attack. Yet in this trial, a post-radiotherapy increase in PD-L1-expressing classical monocytes was associated with benefit. Patients with progression-free survival of three months or longer showed a median fold-increase of 2.8 in these cells after radiation, compared with only 0.7 in the shorter-survival group, a difference significant at p equals 0.0085. One plausible interpretation is that radiation drove a wave of inflammatory monocyte mobilization, and the PD-L1 expression on those cells represented a druggable vulnerability rather than an insurmountable barrier, a target that atezolizumab could engage precisely because the cells were present and ligand-loaded.

Read together, the two signatures suggest that radiotherapy does not simply damage tumors; it measurably reprograms the innate immune compartment in the periphery, and the pattern of that reprogramming predicts who will benefit from subsequent checkpoint blockade. This is a conceptually important shift. Most biomarker research in immunotherapy has concentrated on the tumor itself, examining PD-L1 staining on biopsy specimens, tumor mutational burden, or the density of lymphocyte infiltration. Small cell lung cancer frustrates these approaches because biopsies are difficult to obtain in relapsed patients and the tumor microenvironment is often profoundly immunosuppressed. A blood test that requires only serial peripheral blood draws, analyzed by standard flow cytometry, would be far more practical for a patient population that is often too fragile for repeat invasive procedures.

The trial’s limitations deserve honest framing. Thirty patients is a small cohort, the study was single-arm without a randomized control receiving atezolizumab alone, and the immune correlates were pre-specified as exploratory rather than confirmatory objectives. Correlates identified in a phase II setting must be validated in larger, ideally randomized, cohorts before they can guide clinical decisions. There is also a biological ambiguity to resolve: whether the NKT cell expansion and monocyte PD-L1 induction are causal drivers of benefit, passive readouts of a favorable radiation response, or both. Answering that question will require mechanistic studies that connect the peripheral blood observations to what is happening inside the irradiated tumor and in distant metastatic sites.

Even so, the study adds a meaningful piece to one of the most active puzzles in modern oncology: how to make radiation and immunotherapy work as true partners rather than sequential monotherapies. The abscopal effect, in which localized radiation shrinks tumors far from the treatment field, has tantalized researchers for decades but remains rare in practice, likely because it depends on a permissive immune context that most patients’ tumors and immune systems do not spontaneously provide. Biomarkers like the ones identified here, dynamic and measured in blood, could eventually allow clinicians to identify which patients carry that permissive biology before committing them to combination therapy, and to test interventions, such as altered radiation fractionation or additional immune modulators, in those who do not. For a disease as aggressive and under-served as relapsed small cell lung cancer, even a modest systemic signal paired with a usable predictive signature represents progress worth building on, and the Korean team’s finding that innate immune reprogramming can be tracked in a simple blood sample may prove to be the trial’s most enduring legacy.

Subject of Research: Immune correlates of radiotherapy-primed atezolizumab in relapsed small cell lung cancer

Article Title: Dynamics of peripheral blood NKT cells and PD-L1-expressing classical monocytes as immune correlates of radiotherapy-primed atezolizumab in relapsed small cell lung cancer: a phase II study

Article References: Suh, Y.-G., Lee, Y., Moon, S. H., Lee, S., & Han, J.-Y. (2026). Dynamics of peripheral blood NKT cells and PD-L1-expressing classical monocytes as immune correlates of radiotherapy-primed atezolizumab in relapsed small cell lung cancer: a phase II study. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04570-1

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04570-1

Keywords: small cell lung cancer, atezolizumab, hypofractionated radiotherapy, NKT cells, classical monocytes, PD-L1, immune checkpoint inhibitor, immune biomarkers, phase II trial, radio-immunotherapy, flow cytometry, progression-free survival